CIS Pharma demonstrates successful in-vivo biodistribution study for Oncology drug carrier
Bubendorf, Switzerland -- CIS Pharma successfully completed the biodistribution study with its polymer carrier technology applied to an antibody radionuclide conjugate (ARC). The conjugate was tested in a SKOvip mouse model, an aggressive form of ovarian cancer. The ARC tested comprised Trastuzumab as a model antibody to which two polymer carriers were conjugated that contained several chelators for the immobilization of radionuclides like lutecium-177 or indium-111. The biodistribution including the ratio of tumor to healthy tissue of the conjugate was similar to the Trastuzumab antibody labeled directly with lutecium-177 or indium-111. CIS Pharma’s ARC technology showed a higher stability in blood and higher yields during the conjugation process.
Dr. Martin Behe, Group Leader at the Center for Radiopharmaceutical Sciences (CRS) at the Paul Scherrer Institute, was impressed by the performance of the ARC based on the polymer carrier that showed a good uptake in the tumor tissue and a lower background in other organs compared to the conventional ARC.
Dr Christian Geraths, CSO of CIS Pharma AG, said: “These results clearly indicate that the antibody’s target specificity is unimpaired when we attach our polymer carrier to it. Since the polymer carrier itself can be modified with a multitude of different actives in a far easier and more robust setup, this study represents an important milestone for the next generation of ARCs”. Based on these positive results CIS Pharma will start the development of its own ARC program for a promising new target.”